Navigation Links
JCI early table of contents for April 15, 2013
Date:4/15/2013

Researchers untangle molecular pathology of giant axonal neuropathy

Giant axonal neuropathy (GAN) is a rare genetic disorder that causes central and peripheral nervous system dysfunction. GAN is known to be caused by mutations in the gigaxonin gene and is characterized by tangling and aggregation of neural projections, but the mechanistic link between the genetic mutation and the effects on neurons is unclear. In this issue of the Journal of Clinical Investigation, Robert Goldman and colleagues at Northwestern University uncover how mutations in gigaxonin contribute to neural aggregation.They demonstrated that gigaxonin regulates the degradation of neurofilament proteins, which help to guide outgrowth and morphology of neural projections. Loss of gigaxonin in either GAN patient cells or transgenic mice increased levels of neurofilament proteins, causing tangling and aggregation of neural projections. Importantly, expression of gigaxonin allowed for clearance of neurofilament proteins in neurons. These findings demonstrate that mutations in gigaxonin cause accumulation of neurofilament proteins and shed light on the molecular pathology of GAN.

TITLE: Giant axonal neuropathy-assoicated gigaxonin mutations impair intermediate filament protein degradation

AUTHOR CONTACT:
Robert Goldman
Northwestern University Medical School, Chicago, IL, USA
Phone: 312-503-4215; E-mail: r-goldman@northwestern.edu

View this article at: http://www.jci.org/articles/view/66387?key=fbb27aa987681b6b9d6a


Resistance is futile: researchers identify gene that mediates cisplatin resistance in ovarian cancer

Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but cancer cells frequently develop resistance to these drugs. Mechanisms of resistance typically include reduced platinum uptake and increased platinum export. In this issue of the Journal of Clinical Investigation, Anil Sood and colleagues at M.D. Anderson Cancer Center identified a cellular membrane protein, ATP11B, that mediates cisplatin resistance in ovarian cancer cells. They found that ATP11B expression was correlated with higher tumor grade in human ovarian cancer samples and with cisplatin-resistance in human ovarian cancer cell lines. Further, loss of ATP11B restored the sensitivity of ovarian cancer cell lines to cisplatin and reduced ovarian tumor growth in mice. These findings suggest that ATP11B could serve as a therapeutic target to overcome cisplatin resistance.

TITLE: ATP11B mediates platinum resistance in ovarian cancer

AUTHOR CONTACT:
Anil Sood
M. D. Anderson Cancer Center, Houston, TX, USA
Phone: 713-745-5266; Fax: 713-792-7586; E-mail: asood@mdanderson.org

View this article at: http://www.jci.org/articles/view/65425?key=1b568a84b2ed6f3104ee


ALSO IN THIS ISSUE

TITLE: RNA binding protein PCBP2 modulates glioma growth by regulating FHL3

AUTHOR CONTACT:
Xiaozhong Peng
Institute of Basic Medical Sciences & School of Basic Medicine,Chinese Acad, Beijing, CHN
Phone: 0086-010-65296434; E-mail: peng_xiaozhong@163.com

View this article at: http://www.jci.org/articles/view/61820?key=1198455a7ca0e03c53ba

TITLE: IL-33 dependent induction of allergic lung inflammation by FcγRIII signaling

AUTHOR CONTACT:
Anne Sperling
University of Chicago, Chicago, IL, USA
Phone: 773-834-1211; Fax: 773-702-4736; E-mail: asperlin@uchicago.edu

View this article at: http://www.jci.org/articles/view/63802?key=032761d160603a5e9093

TITLE: WNT signaling underlies the pathogenesis of neuropathic pain in rats

AUTHOR CONTACT:
Xue-Jun Song
Parker University Research Institue, Dallas, , USA
Phone: 9734386932 EXT 7144

View this article at: http://www.jci.org/articles/view/65364?key=b983094cb01c7ee80e34

TITLE: Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs

AUTHOR CONTACT:
Cynthia E. Dunbar
NIH, National Heart, Lung and Blood Institute, Bethesda, MD, USA
Phone: 301 496 1434; Fax: 301-496-8396

View this article at: http://www.jci.org/articles/view/67146?key=2d1d1346d4a5bb96bb80

TITLE: Opposing chemokine gradients control human thymocyte migration in situ

AUTHOR CONTACT:
Ellen Robey
University of California, Berkeley, Berkeley, CA, USA
Phone: 510-642-8669

View this article at: http://www.jci.org/articles/view/67175?key=ea0f0474c71bcec79110

TITLE: GM-CSF contributes to aortic aneurysms resulting from SMAD3 deficiency

AUTHOR CONTACT:
Jiahong Xia
Union Hospital, Tongji Medical College, Huazhong University of Science and, Wuhan, CHN
Phone: 0086-13971038472; Fax: 0086-27- 85726337; E-mail: jiahong.xia@mail.hust.edu.cn

View this article at: http://www.jci.org/articles/view/67356?key=481605675f72b402a894

TITLE: Mer receptor tyrosine kinase is a novel therapeutic target in melanoma

AUTHOR CONTACT:
Douglas Graham
Univ of Colorado Anschutz Medical Campus, Aurora, CO, USA
Phone: 303-724-4006; Fax: 303-724-4015; E-mail: doug.graham@ucdenver.edu

View this article at: http://www.jci.org/articles/view/67816?key=c3beb1f407a41392c648


'/>"/>

Contact: Jillian Hurst
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Fosamax Lawsuit Update: Bernstein Liebhard LLP Notes Nearly 2,600 Claims Alleging Fosamax Femur Fractures, Other Side Effects, Pending in New Jersey State Litigation
2. Living Well Assisted Living at Home Hosts Ongoing Support Group for Patients with Early Onset Alzheimer’s
3. Hospitals Work to Reduce Unnecessary Early Births
4. JCI early table of contents for April 8, 2013
5. Causes of migraines nearly impossible to determine
6. Nearly 30 Percent of Americans Have High Blood Pressure: CDC
7. Cartilage Gives Early Warning of Arthritis, Study Finds
8. JCI early table of contents for April 1, 2013
9. Early COPD diagnosis possible with nuclear medicine
10. Blood Test Might Spot Pancreatic Cancer Early, Study Finds
11. New metabolite-based diagnostic test could help detect pancreatic cancer early
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... 2016 , ... Stephanie Hebert Insurance Agency, serving families of ... charity campaign. As part of their ongoing community involvement program, funds are now ... children deserve a voice, and in the spirit of neighbors helping neighbors in ...
(Date:2/8/2016)... , ... February 08, 2016 , ... A man who has struggled to quit smoking, ... Laser Therapy , was determined to find solutions to his problems – and he did. ... Digest is ready to introduce his breakthrough inventions to the world and better people's ...
(Date:2/8/2016)... York, NY (PRWEB) , ... February 08, 2016 , ... ... are too much to handle, you are not alone. According to the Center for ... include heart disease, stroke, type 2 diabetes and certain types of cancer, some of ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... February 08, 2016 , ... Local ... the greater Venice, FL area, has initiated a fundraiser for a two year ... just four days after Christmas. To support this beautiful child who is facing ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Cardiovascular Surgery Devices - Medical Devices Pipeline Assessment, ... report, "Cardiovascular Surgery Devices - Medical Devices Pipeline ... Devices currently in pipeline stage. ... comprehensive information on the pipeline products with comparative ... development. The report reviews major players involved in ...
(Date:2/8/2016)... 2016  Labvantage Lx, a newcomer to the ... sexual enhancement product, EnduramenT. Setting a new standard ... a patented biomedical breakthrough molecule that promotes the ... responsible for many biological functions including erectile function. ... Forgoing the use of prescription medications, scientists working ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
Breaking Medicine Technology: